MISSION Therapeutics Ltd, a Cambridge, UK-based newly formed company that is developing a broad platform of technologies for the discovery and development of targeting enzymes involved in cancer and other diseases, has raised £6m in a Series A funding.
The round was led by Sofinnova Partners, with participation from Imperial Innovations, SR One and Roche Venture Fund.
The new spin-out company aims to translate cell biology research on DNA repair from Professor Jackson’s laboratory at the Gurdon Institute, University of Cambridge, into drugs designed to improve the management of life-threatening diseases such as cancer. MISSION Therapeutics will predominantly exploit new research on ubiquitin pathways that control cellular responses to DNA damage.
The founding scientists of the company, which will be based on the Babraham Research Campus, Cambridge, UK, include Professor Jackson, Dr Niall Martin, Dr Xavier Jacq and Dr Keith Menear.
FinSMEs
26/08/2011